, ,
Presentations this author is a contributor to:
Patients' and their doctors’ preferences for adjuvant chemotherapy (ACT) in early non-small cell lung cancer (NSCLC): What makes it worthwhile? (#149)
10:00 AM
Sue-Anne McLachlan
COSA Best of the Best Orals: Health Services
Preferences for adjuvant sorafenib after resection of intermediate to high risk renal cell carcinoma of the kidney (#213)
5:00 PM
Prunella Blinman
COSA - Minding your P's and Q's: Psychosocial aspects of urologic cancer